Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.285,03
-0,40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AnaptysBio Inc (ANAB) AnaptysBio Inc (ANAB) Notizie

ANAB

AnaptysBio (ANAB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANAB
DataOraFonteTitoloSimboloCompagnia
18/12/202422:30Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ANABAnaptysBio Inc
11/12/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
11/12/202414:30GlobeNewswire Inc.Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisNASDAQ:ANABAnaptysBio Inc
18/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ANABAnaptysBio Inc
15/11/202422:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANABAnaptysBio Inc
14/11/202415:24Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANABAnaptysBio Inc
05/11/202422:27Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANABAnaptysBio Inc
05/11/202422:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
05/11/202422:15GlobeNewswire Inc.Anaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
05/11/202422:15GlobeNewswire Inc.Anaptys Announces Participation in November and December Investor ConferencesNASDAQ:ANABAnaptysBio Inc
24/09/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
23/09/202422:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANABAnaptysBio Inc
29/08/202415:15GlobeNewswire Inc.Anaptys Announces Participation in September Investor ConferencesNASDAQ:ANABAnaptysBio Inc
16/08/202418:07Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ANABAnaptysBio Inc
14/08/202411:00GlobeNewswire Inc.Anaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingNASDAQ:ANABAnaptysBio Inc
05/08/202422:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANABAnaptysBio Inc
05/08/202422:15GlobeNewswire Inc.Anaptys Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
09/05/202422:15GlobeNewswire Inc.Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
09/05/202422:10GlobeNewswire Inc.Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
09/05/202422:05GlobeNewswire Inc.Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli RoyaltiesNASDAQ:ANABAnaptysBio Inc
06/05/202418:59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANABAnaptysBio Inc
24/04/202415:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:ANABAnaptysBio Inc
11/03/202421:36Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANABAnaptysBio Inc
29/02/202415:15GlobeNewswire Inc.Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual MeetingNASDAQ:ANABAnaptysBio Inc
14/02/202416:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANABAnaptysBio Inc
31/01/202415:15GlobeNewswire Inc.Anaptys to Present at Guggenheim’s 6th Annual Biotechnology ConferenceNASDAQ:ANABAnaptysBio Inc
27/11/202322:15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:ANABAnaptysBio Inc
07/11/202322:15GlobeNewswire Inc.Anaptys Named a BioSpace 2024 Best Places to Work WinnerNASDAQ:ANABAnaptysBio Inc
02/11/202321:15GlobeNewswire Inc.Anaptys Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
01/11/202314:15GlobeNewswire Inc.Anaptys Announces Participation in November Investor ConferencesNASDAQ:ANABAnaptysBio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANAB

La tua Cronologia

LSE
74ZF
Tesco 5.20%
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network